Telix partners with EDAP and Profound on prostate imaging tech
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
May 15, 2026 6:30 AM EDTTelix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.
MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, Profound),... More
